DT&CRO CO., Ltd.
A full-service CRO supporting the entire drug development cycle from non-clinical studies to phase 4 clinical trials and FDA consulting.
As of 2026-10-08, DT&CRO CO., Ltd. has 5 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2017 and listed on KOSDAQ in 2022, DT&CRO is a full-service CRO covering pharmaceuticals, medical devices, health functional foods, cosmetics, and chemicals. It provides end-to-end drug development services from non-clinical studies (efficacy evaluation, animal alternative testing, safety/toxicity testing) through bioequivalence studies, phase 1-4 clinical trials, and U.S. FDA approval consulting, and operates an analysis center offering ADME/DMPK analysis via its PK/PD center. In 2025 revenue was KRW 47.74 billion, up 32.7% year-on-year from KRW 35.97 billion, and its in-house research institute independently developed biosimilar characterization methods for products including human growth hormone, Herceptin, and Avastin, as well as a DAR analysis method for antibody-drug conjugates (ADC).
Products & technology
- Non-clinical trial servicesEfficacy evaluation, animal alternative testing, safety/toxicity testing
- Clinical trial services (Phase 1-4)From verifying human applicability of drug candidates to post-marketing surveillance
- Analysis center services (PK/PD, ADME/DMPK)Clinical/bioequivalence sample analysis, pharmacokinetic and toxicokinetic analysis
Clinical trials
data.go.kr1 MFDS clinical trial authorisations · 2022 (Phase 1/2a 1)
- Phase 1/2aKAT-1012022-03-23
4 trial sites
R&D and key agreements
Source: DART corporate disclosure바이오시밀러 특성분석 · Established mass spectrometry-based characterization methods for originator biologics including human growth hormone, Herceptin, and Avastin
특성분석법 밸리데이션 · Validated characterization methods for specificity, precision, accuracy, and system accuracy
바이오베터 ADC 특성분석 · Established DAR (Drug-Antibody Ratio) analysis method using intact mass analysis
비임상 유효성평가 서비스 확대를 위한 영상기술 확립 · 2022.08~2023.07 · Established imaging technology for non-clinical efficacy evaluation studies for domestic approval
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- Efficacy and safety of Doxycycline versus Macrolides for Mycoplasma pneumoniae INfectiOn in Children (DOMINO): a protocol for a multicentre, randomised, open-label, superiority trial.
BMJ open · 2026-05 · Choi YY, Kang C, Choe YJ 외 23
- Self-assembling polypeptide-drug conjugates as innovative therapeutic candidates for glioblastoma treatment by enhancing intracranial residence time.
Neuro-oncology advances · 2025-01 · Gwon Y, Kim JE, Jung W 외 6
- Comparative analysis of chronic progressive nephropathy (CPN) diagnosis in rat kidneys using an artificial intelligence deep learning model.
Toxicological research · 2024-10 · Bae Y, Byun J, Lee H 외 1
- Evaluation of Caspase-3 and Ki-67 expression in squamous cell hyperplasia of the stomach induced by Platycodi radix water extract in Sprague-Dawley rats.
Journal of toxicologic pathology · 2022-01 · Li Y, Cha SB, Park Y 외 10
- Inhibition of P2X7R-NLRP3 Inflammasome Activation by Pleurotus citrinopileatus: A Possible Protective Role in Alcoholic Hepatosteatosis.
Journal of agricultural and food chemistry · 2018-12 · Li X, Jin Q, Zhang Y 외 12
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive2
- OpenAIOAI-SearchBot25
- AnthropicClaudeBot2
- PerplexityPerplexityBot1
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 4 AI engines · last read Oct 7, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for DT&CRO CO., Ltd. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition